Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23704531 | 0.82 | KDM4C (0.36) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL9923393 | 0.68 | KDM4C (0.37) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL17878832 | 0.68 | KDM4C (0.43) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL7482938 | 0.67 | NPC1 (0.46) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL8321396 | 0.66 | NPC1 (0.50) | NPC1RAB9AKDM4CMEN1KMT2A | |
| SCHEMBL8268349 | 0.66 | NPC1 (0.43) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL29749517 | 0.65 | NPC1 (0.42) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL23388043 | 0.65 | NPC1 (0.42) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL9449669 | 0.65 | AGXT (0.51) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL14065905 | 0.65 | ICAM1 (0.42) | NPC1RAB9AKDM4CL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4097092-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | Protego Biopharma, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115298168-A | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | 普罗泰格生物制药公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021154842-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | TTR, TTPA, TNNC1 | NPC1 684/4885RAB9A 3065/4885KDM4C 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.